NASDAQ: UPCUniverse Pharmaceuticals Inc Stock
$0.90+0.00 (+0%)
Updated Jun 9, 2023
UPC Price
$0.90
Fair Value Price
N/A
Market Cap
$19.49M
52 Week Low
$0.48
52 Week High
$2.08
P/E
-2.24x
P/B
0.42x
P/S
0.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$40.14M
Earnings
-$8.74M
Gross Margin
54.5%
Operating Margin
-19.48%
Profit Margin
-21.8%
Debt to Equity
0.28
Operating Cash Flow
-$1M
Beta
0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UPC Overview
Universe Pharmaceuticals Incorporated sells traditional Chinese medicines in China. It offers treatments of common chronic health conditions in the elderly and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. Universe Pharmaceuticals was incorporated in 2019 and is based in Ji'An, PRC.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UPC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UPC is good value based on its book value relative to its share price (0.42x), compared to the US Biotechnology industry average (5.2x)
P/B vs Industry Valuation
UPC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more UPC due diligence checks available for Premium users.
Be the first to know about important UPC news, forecast changes, insider trades & much more!
UPC News
Valuation
UPC fair value
Fair Value of UPC stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$0.77
Overvalued by
16.58%
UPC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UPC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.24x
Industry
11.33x
Market
52.94x
UPC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
5.2x
UPC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UPC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
UPC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
UPC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.5M
Liabilities
$13.1M
Debt to equity
0.28
UPC's short-term assets ($41.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPC's short-term assets ($41.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
UPC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UPC vs Biotech Stocks
Universe Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.